Table 2.
Baseline characteristics before starting treatment with Ra-223
| Patient | Metastatic sites | Mean SUVmax (Range) | PSA (ng/ml) | ALP (UI/L) | LDH (UI/L) | VAS | Hb (g/dl) | Plt (× 103/µL) | Neutrophils (× 103/µL) | Leukocytes (× 103/µL) | Previous RT |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SUPERSCAN | 91.6 (79.1-144.1) | 3.2 | 270 | 181 | 8 | 13.3 | 286 | 4.5 | 7.2 | NO |
| 2 | 15 | 66.8 (26.9-84.2) | 34 | 196 | 189 | 8 | 12.9 | 190 | 4.1 | 5.5 | SI |
| 3 | 12 | 58.7 (22.5-76.4) | 26 | 348 | 207 | 8 | 14.8 | 323 | 5.4 | 5.1 | NO |
| 4 | > 20 | 81.7 (33.1-91.9) | 36.4 | 160 | 291 | 8 | 14.2 | 263 | 3.8 | 7.3 | NO |
| 5 | 18 | 69.1 (36.9-101.2) | 18.3 | 455 | 299 | 7 | 11.1 | 328 | 3.2 | 4.2 | NO |
| 6 | > 20 | 89.7 (53.1-101.6) | 6.7 | 211 | 189 | 7 | 13.1 | 401 | 3.7 | 4.5 | NO |
| 7 | SUPERSCAN | 96.6 (84.7-155.0) | 71 | 901 | 604 | 7 | 12.1 | 388 | 2.9 | 3.1 | SI |
RT: Radiotherapy; Hb: Hemoglobin; Plt: platelets.